2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 877

Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis
Abstract Number: 2646

Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): A Systematic Review and Meta-Analysis
Abstract Number: 1195

Risk of Hospitalized Infection Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
Abstract Number: 3066

Risk of Incident Cancer with Biologic and Tofacitinib Therapy in Rheumatoid Arthritis
Abstract Number: 1991

Risk of Incident Diabetes Mellitus and Its Association with Disease-Modifying Antirheumatic Drugs and Statins in Rheumatoid Arthritis
Abstract Number: 3116

Risk of Infections in Juvenile Idiopathic Arthritis Patients Treated with Biologic Agentsand/or Methotrexate: Results from Pharmachild Registry
Abstract Number: 2029

Risk of Knee Pain, Radiographic Osteoarthritis and Knee Arthroplasty in Retired Professional Footballers Compared to the General Population
Abstract Number: 2813

Risk of Renal Failure within 10 or 20 Years of SLE Diagnosis, By Patient Characteristics
Abstract Number: 988

Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: 29

Risk of Vascular Mortality in Seniors with New-Onset Rheumatoid Arthritis
Abstract Number: 2939

Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis
Abstract Number: 763

Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus
Abstract Number: 907

Rituximab in Patients with Takayasu Arteritis: A Single Center Experience on Five Patients
Abstract Number: 259

Rituximab in Refractory Cardiac Sarcoidosis – Single Center Experience
Abstract Number: 2904

Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].